Newly identified biologically active and proteolysis-resistant VEGF-A isoform VEGF111 is induced by genotoxic agents

Journal of Cell Biology

Volumn 179, Issue 6, 2007, Pages 1261-1273

  Mineur, Pierre ^a   Colige, Alain C ^a   Deroanne, Christophe F ^a   Dubail, Johanne ^a   Kesteloot, Frédéric ^a   Habraken, Yvette ^a   Noël, Agnès ^a   Vöö, Stefan ^b   Waltenberger, Johannes ^b   Lapière, Charles M ^a   Nusgens, Betty V ^a   Lambert, Charles A ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CAMPTOTHECIN; ISOPROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; RECOMBINANT VASCULOTROPIN; TOXIN; UNCLASSIFIED DRUG; VASCULAR ENDOTHELIAL GROWTH FACTOR 111; VASCULOTROPIN 121; VASCULOTROPIN 165; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; AORTA; ARTICLE; BIOLOGICAL ACTIVITY; CELL CULTURE; CELL DIFFERENTIATION; CELL STRAIN HEK293; CELL STRAIN MCF 7; CHEMOTAXIS; CONTROLLED STUDY; DIFFUSION; DRUG MECHANISM; EMBRYO; EMBRYONIC STEM CELL; ENDOTHELIUM CELL; EXON; EXTRACELLULAR MATRIX; GENOTOXICITY; HUMAN; HUMAN CELL; MITOGENESIS; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECEPTOR UPREGULATION; SWINE; TUMOR VASCULARIZATION; TUMOR XENOGRAFT; ULTRAVIOLET B RADIATION; UMBILICUS; VASCULARIZATION;

ANIMALS; ANOXIA; APOPTOSIS; CAMPTOTHECIN; DNA DAMAGE; ENZYME INHIBITORS; GENE EXPRESSION; GLYCOSYLATION; HUMANS; HYPOGLYCEMIA; MICE; MICE, NUDE; MUTAGENS; NEOVASCULARIZATION, PATHOLOGIC; PROTEIN ISOFORMS; REACTIVE OXYGEN SPECIES; RNA, MESSENGER; SWINE; ULTRAVIOLET RAYS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

MUS MUSCULUS; SUS;

EID: 37249059009     PISSN: 00219525     EISSN: 00219525     Source Type: Journal    
DOI: 10.1083/jcb.200703052     Document Type: Article

References (40)

1. Bates, D.O., T.G. Cui, J.M. Doughty, M. Winkler, M. Sugiono, J.D. Shields, D. Peat, D. Gillatt, and S.J. Harper. 2002. VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma. Cancer Res. 62:4123-4131.
2. Blaudschun, R., C. Sunderkotter, P. Brenneisen, R. Hinrichs, T. Peters, L. Schneider, Z. Razi-Wolf, N. Hunzelmann, and K. Scharffetter-Kochanek. 2002. Vascular endothelial growth factor causally contributes to the angiogenic response upon ultraviolet B irradiation in vivo. Br. J. Dermatol. 146:581-587.
3. Brown, L.F., K.T. Yeo, B. Berse, T.K. Yeo, D.R. Senger, H.F. Dvorak, and L. van de Water. 1992. Expression of vascular permeability factor (vascular endothelial growth factor) by epidermal keratinocytes during wound healing. J. Exp. Med. 176:1375-1379.
4. Burchardt, M., T. Burchardt, A.G. Anastasiadis, R. Buttyan, A. de la Taille, A. Shabsigh, J. Frank, and R. Shabsigh. 2005. Application of angiogenic factors for therapy of erectile dysfunction: protein and DNA transfer of VEGF 165 into the rat penis. Urology. 66:665-670.
5. Caldwell, R.B., M. Bartoli, M.A. Behzadian, A.E. El-Remessy, M. Al-Shabrawey, D.H. Platt, G.I. Liou, and R.W. Caldwell. 2005. Vascular endothelial growth factor and diabetic retinopathy: role of oxidative stress. Curr. Drug Targets. 6:511-524.
6. Carmeliet, P., V. Ferreira, G. Breier, S. Pollefeyt, L. Kieckens, M. Gertsenstein, M. Fahrig, A. Vandenhoeck, K. Harpal, C. Eberhardt, et al. 1996. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature. 380:435-439.
7. Chirgwin, J.M., A.E. Przybyla, R.J. MacDonald, and W.J. Rutter. 1979. Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry. 18:5294-5299.
8. Claffey, K.P., D.R. Senger, and B.M. Spiegelman. 1995. Structural requirements for dimerization, glycosylation, secretion, and biological function of VPF/VEGF. Biochim. Biophys. Acta. 1246:1-9.
9. Colige, A., F. Ruggiero, I. Vandenberghe, J. Dubail, F. Kesteloot, J. Van Beeumen, A. Beschin, L. Brys, C.M. Lapiere, and B. Nusgens. 2005. Domains and maturation processes that regulate the activity of ADAMTS-2, a metalloproteinase cleaving the aminopropeptide of fibrillar procollagens types I-III and V. J. Biol. Chem. 280:34397-34408.
10. Deroanne, C.F., K. Bonjean, S. Servotte, L. Devy, A. Colige, N. Clausse, S. Blacher, E. Verdin, J.M. Foidart, B.V. Nusgens, and V. Castronovo. 2002. Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling. Oncogene. 21:427-436.
11. Dvorak, H.F. 2000. VPF/VEGF and the angiogenic response. Semin. Perinatol. 24:75-78.
12. Ferrara, N. 2005. VEGF as a therapeutic target in cancer. Oncology. 69:11-16.
13. Ferrara, N., K. Carver-Moore, H. Chen, M. Dowd, L. Lu, K.S. O'Shea, L. Powell-Braxton, K.J. Hillan, and M.W. Moore. 1996. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature. 380:439-442.
14. Hajitou, A., N.E. Sounni, L. Devy, C. Grignet-Debrus, J.M. Lewalle, H. Li, C.F. Deroanne, H. Lu, A. Colige, and B.V. Nusgens, et al. 2001. Down-regulation of vascular endothelial growth factor by tissue inhibitor of metalloproteinase-2: effect on in vivo mammary tumor growth and angiogenesis. Cancer Res. 61:3450-3457.
15. Hattori-Nakakuki, Y., C. Nishigori, K. Okamoto, S. Imamura, H. Hiai, and S. Toyokuni. 1994. Formation of 8-hydroxy-2′-deoxyguanosine in epidermis of hairless mice exposed to near-UV. Biochem. Biophys. Res. Commun. 201:1132-1139.
16. Houck, K.A., N. Ferrara, J. Winer, G. Cachianes, B. Li, and D.W. Leung. 1991. The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol. Endocrinol. 5:1806-1814.
17. Jingjing, L., Y. Xue, N. Agarwal, and R.S. Roque. 1999. Human Muller cells express VEGF183, a novel spliced variant of vascular endothelial growth factor. Invest. Ophthalmol. Vis. Sci. 40:752-759.
18. Katiyar, S.K., B.M. Bergamo, P.K. Vyalil, and C.A. Elmets. 2001. Green tea polyphenols: DNA photodamage and photoimmunology. J. Photochem. Photobiol. B. 65:109-114.
19. Keyt, B.A., L.T. Berleau, H.V. Nguyen, H. Chen, H. Heinsohn, R. Vandlen, and N. Ferrara. 1996. The carboxyl-terminal domain (111-165) of vascular endothelial growth factor is critical for its mitogenic potency. J. Biol. Chem. 271:7788-7795.
20. Lambert, C.A., A.C. Colige, C. Munaut, C.M. Lapiere, and B.V. Nusgens. 2001. Distinct pathways in the over-expression of matrix metalloproteinases in human fibroblasts by relaxation of mechanical tension. Matrix Biol. 20:397-408.
21. Lauer, G., S. Sollberg, M. Cole, I. Flamme, J. Sturzebecher, K. Mann, T. Krieg, and S.A. Eming. 2000. Expression and proteolysis of vascular endothelial growth factor is increased in chronic wounds. J. Invest. Dermatol. 115:12-18.
22. Lauer, G., S. Sollberg, M. Cole, T. Krieg, and S.A. Eming. 2002. Generation of a novel proteolysis resistant vascular endothelial growth factor165 variant by a site-directed mutation at the plasmin sensitive cleavage site. FEBS Lett. 531:309-313.
23. Lee, S., S.M. Jilani, G.V. Nikolova, D. Carpizo, and M.L. Iruela-Arispe. 2005. Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors. J. Cell Biol. 169:681-691.
24. Maity, A., N. Pore, J. Lee, D. Solomon, and D.M. O'Rourke. 2000. Epidermal growth factor receptor transcriptionally up-regulates vascular endothelial growth factor expression in human glioblastoma cells via a pathway involving phosphatidylinositol 3′-kinase and distinct from that induced by hypoxia. Cancer Res. 60:5879-5886.
25. Mineur, P., A. Guignandon, C.A. Lambert, M. Amblard, C.M. Lapiere, and B.V. Nusgens. 2005. RGDS and DGEA-induced [Ca2+]i signalling in human dermal fibroblasts. Biochim. Biophys. Acta. 1746:28-37.
26. Park, J.E., G.A. Keller, and N. Ferrara. 1993. The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. Mol. Biol. Cell. 4:1317-1326.
27. Peretz, D., H. Gitay-Goren, M. Safran, N. Kimmel, D. Gospodarowicz, and G. Neufeld. 1992. Glycosylation of vascular endothelial growth factor is not required for its mitogenic activity. Biochem. Biophys. Res. Commun. 182:1340-1347.
28. Robinson, C.J., and S.E. Stringer. 2001. The splice variants of vascular endothelial growth factor (VEGF) and their receptors. J. Cell Sci. 114:853-865.
29. Roth, D., M. Piekarek, M. Paulsson, H. Christ, T. Krieg, W. Bloch, J.M. Davidson, and S.A. Eming. 2006. Plasmin modulates vascular endothelial growth factor-A-mediated angiogenesis during wound repair. Am. J. Pathol. 168:670-684.
30. Skobe, M., P. Rockwell, N. Goldstein, S. Vosseler, and N.E. Fusenig. 1997. Halting angiogenesis suppresses carcinoma cell invasion. Nat. Med. 3:1222-1227.
31. Soker, S., S. Gollamudi-Payne, H. Fidder, H. Charmahelli, and M. Klagsbrun. 1997. Inhibition of vascular endothelial growth factor (VEGF)-induced endothelial cell proliferation by a peptide corresponding to the exon 7-encoded domain of VEGF165. J. Biol. Chem. 272:31582-31588.
32. Soker, S., S. Takashima, H.Q. Miao, G. Neufeld, and M. Klagsbrun. 1998. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell. 92:735-745.
33. Sounni, N.E., L. Devy, A. Hajitou, F. Frankenne, C. Munaut, C. Gilles, C. Deroanne, E.W. Thompson, J.M. Foidart, and A. Noel. 2002. MT1-MMP expression promotes tumor growth and angiogenesis through an up-regulation of vascular endothelial growth factor expression. FASEB J. 16:555-564.
34. Stadler, N., J. Eggermann, S. Voo, A. Kranz, and J. Waltenberger. 2007. Smoking-induced monocyte dysfunction is reversed by vitamin C supplementation in vivo. Arterioscler. Thromb. Vasc. Biol. 27:120-126.
35. Stein, I., M. Neeman, D. Shweiki, A. Itin, and E. Keshet. 1995. Stabilization of vascular endothelial growth factor mRNA by hypoxia and hypoglycemia and coregulation with other ischemia-induced genes. Mol. Cell. Biol. 15:5363-5368.
36. von Wronski, M.A., N. Raju, R. Pillai, N.J. Bogdan, E.R. Marinelli, P. Nanjappan, K. Ramalingam, T. Arunachalam, S. Eaton, K.E. Linder, et al. 2006. Tuftsin binds neuropilin-1 through a sequence similar to that encoded by exon 8 of vascular endothelial growth factor. J. Biol. Chem. 281:5702-5710.
37. Waltenberger, J., L. Claesson-Welsh, A. Siegbahn, M. Shibuya, and C.H. Heldin. 1994. Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J. Biol. Chem. 269:26988-26995.
38. Whittle, C., K. Gillespie, R. Harrison, P.W. Mathieson, and S. Harper. 1999. Heterogeneous vascular endothelial growth factor (VEGF) isoform mRNA and receptor mRNA expression in human glomeruli, and the identification of VEGF148 mRNA, a novel truncated splice variant. Clin. Sci. (Lond.). 97:303-312.
39. Yoon, Y.S., I.A. Johnson, J.S. Park, L. Diaz, and D.W. Losordo. 2004. Therapeutic myocardial angiogenesis with vascular endothelial growth factors. Mol. Cell. Biochem. 264:63-74.
40. Zeng, G., S.M. Taylor, J.R. McColm, N.C. Kappas, J.B. Kearney, L.H. Williams, M.E. Hartnett, and V.L. Bautch. 2007. Orientation of endothelial cell division is regulated by VEGF signaling during blood vessel formation. Blood. 109:1345-1352.